We talked with Dr. Tim Oldham about the prospects of AdAlta’s lead compound AD-214 as it enters the clinic for its first Phase 1 study, as well as the power of AdAlta’s i-body drug discovery platform.
We talked with Dr. Tim Oldham about the prospects of AdAlta’s lead compound AD-214 as it enters the clinic for its first Phase 1 study, as well as the power of AdAlta’s i-body drug discovery platform.
the Kick-ass Multipurpose WordPress Theme